BLA 019676 · Genentech
Nutropin
Somatropin [Rdna Origin] · Injection
OrphanLast checked: Nov 19, 2026Latest source record: Dec 13, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Mar 9, 1994
Approved uses
6
Original approval plus efficacy supplements
Registered trials
n/a
n/a Phase 3, n/a recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 23, 2006 Supplement 26 · Efficacy LetterLabel
- Jun 28, 2005 Supplement 20 · Efficacy LabelLetterLabel
- Apr 13, 2000 Supplement 16 · Efficacy ReviewLetterLabel
- Dec 1, 1999 Supplement 13 · Efficacy ReviewLetter
- Dec 15, 1997 Supplement 9 · Efficacy
- Mar 9, 1994 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
1 products under this application
- NUTROPIN · SOMATROPIN [rDNA origin] N/A · Injectable, Injection · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Somatropin [Rdna Origin]" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns.
Gilpin DA, Barrow RE, Rutan RL, et al. · Ann Surg 1994 · Clinical Trial, Randomized Controlled Trial
- Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
Kemp SF, Fielder PJ, Attie KM, et al. · J Clin Endocrinol Metab 2004 · Clinical Trial, Randomized Controlled Trial
- A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection.
Lee PD, Pivarnik JM, Bukar JG, et al. · J Clin Endocrinol Metab 1996 · Clinical Trial, Multicenter Study
- A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency.
Silverman BL, Blethen SL, Reiter EO, et al. · J Pediatr Endocrinol Metab 2002 · Clinical Trial, Multicenter Study
- Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group.
Powell DR, Liu F, Baker BK, et al. · Kidney Int 1997 · Clinical Trial, Multicenter Study
- A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis.
Stalvey MS, Anbar RD, Konstan MW, et al. · Pediatr Pulmonol 2012 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.